A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 2, 2003, Pages 453-457

  Johnson, Melissa D ^a   Hamilton, Carol D ^a   Drew, Richard H ^a   Sanders, Linda L ^a   Pennick, Gennethel J ^b   Perfect, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Itraconazole; Omeprazole; Pharmacokinetics

Indexed keywords

ASTEMIZOLE; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; CYCLOSPORIN A; DIAZEPAM; DIDANOSINE; DIGOXIN; DRUG METABOLITE; FELODIPINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYITRACONAZOLE; ISONIAZID; ITRACONAZOLE; MEVINOLIN; MIDAZOLAM; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PROTON PUMP INHIBITOR; QUINIDINE; RIFABUTIN; RIFAMPICIN; SIMVASTATIN; TACROLIMUS; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; VINCRISTINE; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANTI-ULCER AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; DRUG INTERACTIONS; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; OMEPRAZOLE; PHARMACEUTICAL SOLUTIONS;

EID: 0037326511     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg089     Document Type: Article

References (12)

1. Willems, L., van der Geest, R. & de Beule, K. (2001). Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. Journal of Clinical Pharmacy and Therapeutics 26, 159-69.
2. Chapman, S. W., Bradsher, R. W., Jr, Campbell, G. D., Jr, Pappas, P. G. & Kauffman, C. A. (2000). Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clinical Infectious Diseases 30, 679-83.
3. van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D. et al. (1997). Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. New England Journal of Medicine 337, 15-21.
4. Stevens, D. A., Kan, V. L., Judson, M. A., Morrison, V. A., Dummer, S., Denning, D. W. et al. (2000). Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clinical Infectious Diseases 30, 696-709.
5. Galgiani, J. N., Ampel, N. M., Catanzaro, A., Johnson, R. H., Stevens, D. A. & Williams, P. L. (2000). Practice guidelines for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clinical Infectious Diseases 30, 658-61.
6. Wilde, M. I. & McTavish, D. (1994). Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 48, 91-132.
7. Jaruratanasirikul, S. & Sriwiriyajan, S. (1998). Effect of omeprazole on the pharmacokinetics of itraconazole. European Journal of Clinical Pharmacology 54, 159-61.
8. Woestenborghs, R., Lorreyne, W. & Heykants, J. (1987). Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. Journal of Chromatography 413, 332-7.
9. Pocock, S. J. (1984). Clinical Trials. John Wiley & Sons, Ltd, Hoboken, NJ, USA.
10. Haria, M., Bryson, H. M. & Goa, K. L. (1996). Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51, 585-620.
11. Harousseau, J. L., Dekker, A. W., Stamatoullas-Bastard, A., Fassas, A., Linkesch, W., Gouveia, J. et al. (2000). Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrobial Agents and Chemotherapy 44, 1887-93.
12. Zhou, Q., Yamamoto, I., Fukuda, T., Ohno, M., Sumida, A. & Azuma, J. (1999). CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. European Journal of Clinical Pharmacology 55, 43-7.